nodes	percent_of_prediction	percent_of_DWPC	metapath
Tolcapone—CYP2C9—Capecitabine—esophageal cancer	0.261	0.665	CbGbCtD
Tolcapone—CYP2C9—Cisplatin—esophageal cancer	0.131	0.335	CbGbCtD
Tolcapone—COMT—Neurotransmitter Clearance In The Synaptic Cleft—ALDH2—esophageal cancer	0.0174	0.149	CbGpPWpGaD
Tolcapone—COMT—Estrogen metabolism—CYP1B1—esophageal cancer	0.00688	0.0589	CbGpPWpGaD
Tolcapone—Tolmetin—PTGS1—esophageal cancer	0.00532	0.636	CrCbGaD
Tolcapone—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.00338	0.0289	CbGpPWpGaD
Tolcapone—CYP2C9—CYP2E1 reactions—CYP2A6—esophageal cancer	0.00325	0.0278	CbGpPWpGaD
Tolcapone—COMT—Phase II conjugation—GSTO1—esophageal cancer	0.00313	0.0268	CbGpPWpGaD
Tolcapone—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.00308	0.0263	CbGpPWpGaD
Tolcapone—Tolmetin—PTGS2—esophageal cancer	0.00304	0.364	CrCbGaD
Tolcapone—COMT—Phase II conjugation—GSTT1—esophageal cancer	0.00243	0.0208	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—ADH7—esophageal cancer	0.00242	0.0207	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—ADH1B—esophageal cancer	0.00212	0.0181	CbGpPWpGaD
Tolcapone—CYP2C9—Xenobiotics—CYP2A6—esophageal cancer	0.00201	0.0172	CbGpPWpGaD
Tolcapone—Ear pain—Capecitabine—esophageal cancer	0.00198	0.00409	CcSEcCtD
Tolcapone—COMT—Biological oxidations—CYP26A1—esophageal cancer	0.00197	0.0168	CbGpPWpGaD
Tolcapone—Sleep disorder—Capecitabine—esophageal cancer	0.00195	0.00404	CcSEcCtD
Tolcapone—COMT—Metapathway biotransformation—CYP26A1—esophageal cancer	0.00194	0.0166	CbGpPWpGaD
Tolcapone—Diabetes mellitus—Capecitabine—esophageal cancer	0.00194	0.00402	CcSEcCtD
Tolcapone—CYP2C9—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00194	0.0166	CbGpPWpGaD
Tolcapone—Musculoskeletal stiffness—Methotrexate—esophageal cancer	0.00193	0.00399	CcSEcCtD
Tolcapone—Sweating increased—Cisplatin—esophageal cancer	0.00193	0.00399	CcSEcCtD
Tolcapone—Polyuria—Capecitabine—esophageal cancer	0.00192	0.00398	CcSEcCtD
Tolcapone—Skin discolouration—Methotrexate—esophageal cancer	0.00191	0.00397	CcSEcCtD
Tolcapone—Gastroenteritis—Capecitabine—esophageal cancer	0.0019	0.00394	CcSEcCtD
Tolcapone—Oliguria—Methotrexate—esophageal cancer	0.00188	0.00389	CcSEcCtD
Tolcapone—Herpes simplex—Methotrexate—esophageal cancer	0.00188	0.00389	CcSEcCtD
Tolcapone—Eye pain—Capecitabine—esophageal cancer	0.00187	0.00387	CcSEcCtD
Tolcapone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00185	0.0158	CbGpPWpGaD
Tolcapone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00185	0.0158	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—GSTO1—esophageal cancer	0.00183	0.0157	CbGpPWpGaD
Tolcapone—Libido decreased—Capecitabine—esophageal cancer	0.00182	0.00377	CcSEcCtD
Tolcapone—COMT—Metapathway biotransformation—GSTO1—esophageal cancer	0.00181	0.0154	CbGpPWpGaD
Tolcapone—Amnesia—Capecitabine—esophageal cancer	0.00179	0.00372	CcSEcCtD
Tolcapone—Atrial fibrillation—Capecitabine—esophageal cancer	0.00178	0.00369	CcSEcCtD
Tolcapone—Thirst—Capecitabine—esophageal cancer	0.00177	0.00367	CcSEcCtD
Tolcapone—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00174	0.0036	CcSEcCtD
Tolcapone—Arthritis—Capecitabine—esophageal cancer	0.00173	0.00359	CcSEcCtD
Tolcapone—CYP2C9—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00173	0.0148	CbGpPWpGaD
Tolcapone—Vaginal inflammation—Methotrexate—esophageal cancer	0.00173	0.00358	CcSEcCtD
Tolcapone—Pulmonary embolism—Methotrexate—esophageal cancer	0.00173	0.00358	CcSEcCtD
Tolcapone—Myocardial infarction—Cisplatin—esophageal cancer	0.00173	0.00358	CcSEcCtD
Tolcapone—Neuropathy peripheral—Cisplatin—esophageal cancer	0.00173	0.00358	CcSEcCtD
Tolcapone—Cardiac failure—Capecitabine—esophageal cancer	0.00173	0.00358	CcSEcCtD
Tolcapone—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00172	0.00356	CcSEcCtD
Tolcapone—Lethargy—Capecitabine—esophageal cancer	0.00172	0.00356	CcSEcCtD
Tolcapone—Stomatitis—Cisplatin—esophageal cancer	0.00172	0.00356	CcSEcCtD
Tolcapone—Diplopia—Capecitabine—esophageal cancer	0.00169	0.00349	CcSEcCtD
Tolcapone—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.00169	0.00349	CcSEcCtD
Tolcapone—Osteoarthritis—Capecitabine—esophageal cancer	0.00169	0.00349	CcSEcCtD
Tolcapone—Disturbance in sexual arousal—Capecitabine—esophageal cancer	0.00167	0.00347	CcSEcCtD
Tolcapone—Migraine—Capecitabine—esophageal cancer	0.00166	0.00344	CcSEcCtD
Tolcapone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00165	0.0141	CbGpPWpGaD
Tolcapone—Vaginal infection—Methotrexate—esophageal cancer	0.00163	0.00338	CcSEcCtD
Tolcapone—Face oedema—Capecitabine—esophageal cancer	0.00163	0.00337	CcSEcCtD
Tolcapone—Bradycardia—Cisplatin—esophageal cancer	0.00161	0.00334	CcSEcCtD
Tolcapone—Irritability—Capecitabine—esophageal cancer	0.00161	0.00333	CcSEcCtD
Tolcapone—Cardiac arrest—Capecitabine—esophageal cancer	0.0016	0.00332	CcSEcCtD
Tolcapone—Urinary retention—Capecitabine—esophageal cancer	0.0016	0.00332	CcSEcCtD
Tolcapone—Mood swings—Capecitabine—esophageal cancer	0.0016	0.00331	CcSEcCtD
Tolcapone—Dehydration—Capecitabine—esophageal cancer	0.00157	0.00325	CcSEcCtD
Tolcapone—Neoplasm—Methotrexate—esophageal cancer	0.00156	0.00324	CcSEcCtD
Tolcapone—Urine output increased—Methotrexate—esophageal cancer	0.00156	0.00324	CcSEcCtD
Tolcapone—Mouth ulceration—Methotrexate—esophageal cancer	0.00156	0.00324	CcSEcCtD
Tolcapone—Urinary tract disorder—Cisplatin—esophageal cancer	0.00156	0.00324	CcSEcCtD
Tolcapone—CYP2C9—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00156	0.0134	CbGpPWpGaD
Tolcapone—Urethral disorder—Cisplatin—esophageal cancer	0.00155	0.00321	CcSEcCtD
Tolcapone—Pulmonary oedema—Methotrexate—esophageal cancer	0.00154	0.00319	CcSEcCtD
Tolcapone—COMT—Biological oxidations—ALDH2—esophageal cancer	0.00149	0.0128	CbGpPWpGaD
Tolcapone—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00149	0.00308	CcSEcCtD
Tolcapone—Tinnitus—Cisplatin—esophageal cancer	0.00148	0.00306	CcSEcCtD
Tolcapone—Dysphagia—Capecitabine—esophageal cancer	0.00146	0.00302	CcSEcCtD
Tolcapone—Asthma—Capecitabine—esophageal cancer	0.00146	0.00302	CcSEcCtD
Tolcapone—Influenza—Capecitabine—esophageal cancer	0.00146	0.00302	CcSEcCtD
Tolcapone—Diabetes mellitus—Methotrexate—esophageal cancer	0.00144	0.00299	CcSEcCtD
Tolcapone—Polyuria—Methotrexate—esophageal cancer	0.00143	0.00296	CcSEcCtD
Tolcapone—Mediastinal disorder—Cisplatin—esophageal cancer	0.00143	0.00295	CcSEcCtD
Tolcapone—COMT—Biological oxidations—GSTT1—esophageal cancer	0.00142	0.0121	CbGpPWpGaD
Tolcapone—Sweating increased—Capecitabine—esophageal cancer	0.00142	0.00294	CcSEcCtD
Tolcapone—Angina pectoris—Capecitabine—esophageal cancer	0.00142	0.00294	CcSEcCtD
Tolcapone—Arrhythmia—Cisplatin—esophageal cancer	0.00141	0.00293	CcSEcCtD
Tolcapone—COMT—Transmission across Chemical Synapses—GNG7—esophageal cancer	0.00141	0.0121	CbGpPWpGaD
Tolcapone—COMT—Biological oxidations—CYP2A6—esophageal cancer	0.0014	0.012	CbGpPWpGaD
Tolcapone—Bronchitis—Capecitabine—esophageal cancer	0.0014	0.0029	CcSEcCtD
Tolcapone—Alopecia—Cisplatin—esophageal cancer	0.0014	0.0029	CcSEcCtD
Tolcapone—CYP2C9—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00138	0.0118	CbGpPWpGaD
Tolcapone—Dysuria—Capecitabine—esophageal cancer	0.00136	0.00282	CcSEcCtD
Tolcapone—Flatulence—Cisplatin—esophageal cancer	0.00136	0.00281	CcSEcCtD
Tolcapone—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.00135	0.00281	CcSEcCtD
Tolcapone—COMT—Biological oxidations—PTGS1—esophageal cancer	0.00133	0.0114	CbGpPWpGaD
Tolcapone—Muscle spasms—Cisplatin—esophageal cancer	0.00132	0.00274	CcSEcCtD
Tolcapone—CYP2C9—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00132	0.0113	CbGpPWpGaD
Tolcapone—COMT—Transmission across Chemical Synapses—ALDH2—esophageal cancer	0.00132	0.0113	CbGpPWpGaD
Tolcapone—Weight decreased—Capecitabine—esophageal cancer	0.00132	0.00273	CcSEcCtD
Tolcapone—Pneumonia—Capecitabine—esophageal cancer	0.00131	0.00271	CcSEcCtD
Tolcapone—Infestation—Capecitabine—esophageal cancer	0.0013	0.00269	CcSEcCtD
Tolcapone—Infestation NOS—Capecitabine—esophageal cancer	0.0013	0.00269	CcSEcCtD
Tolcapone—Vision blurred—Cisplatin—esophageal cancer	0.0013	0.00269	CcSEcCtD
Tolcapone—Tremor—Cisplatin—esophageal cancer	0.00129	0.00267	CcSEcCtD
Tolcapone—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00128	0.00265	CcSEcCtD
Tolcapone—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00128	0.00265	CcSEcCtD
Tolcapone—Lethargy—Methotrexate—esophageal cancer	0.00128	0.00265	CcSEcCtD
Tolcapone—Ill-defined disorder—Cisplatin—esophageal cancer	0.00128	0.00265	CcSEcCtD
Tolcapone—Neuropathy peripheral—Capecitabine—esophageal cancer	0.00127	0.00264	CcSEcCtD
Tolcapone—Myocardial infarction—Capecitabine—esophageal cancer	0.00127	0.00264	CcSEcCtD
Tolcapone—Anaemia—Cisplatin—esophageal cancer	0.00127	0.00264	CcSEcCtD
Tolcapone—Stomatitis—Capecitabine—esophageal cancer	0.00127	0.00262	CcSEcCtD
Tolcapone—Urinary tract infection—Capecitabine—esophageal cancer	0.00126	0.00262	CcSEcCtD
Tolcapone—Osteoarthritis—Methotrexate—esophageal cancer	0.00126	0.0026	CcSEcCtD
Tolcapone—Malaise—Cisplatin—esophageal cancer	0.00124	0.00257	CcSEcCtD
Tolcapone—Haematuria—Capecitabine—esophageal cancer	0.00124	0.00257	CcSEcCtD
Tolcapone—Epistaxis—Capecitabine—esophageal cancer	0.00123	0.00254	CcSEcCtD
Tolcapone—Irritability—Methotrexate—esophageal cancer	0.0012	0.00248	CcSEcCtD
Tolcapone—Mood swings—Methotrexate—esophageal cancer	0.00119	0.00246	CcSEcCtD
Tolcapone—Bradycardia—Capecitabine—esophageal cancer	0.00119	0.00246	CcSEcCtD
Tolcapone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00117	0.01	CbGpPWpGaD
Tolcapone—Myalgia—Cisplatin—esophageal cancer	0.00117	0.00243	CcSEcCtD
Tolcapone—Haemoglobin—Capecitabine—esophageal cancer	0.00117	0.00243	CcSEcCtD
Tolcapone—Rhinitis—Capecitabine—esophageal cancer	0.00117	0.00242	CcSEcCtD
Tolcapone—Anxiety—Cisplatin—esophageal cancer	0.00117	0.00242	CcSEcCtD
Tolcapone—CYP2C9—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00117	0.00999	CbGpPWpGaD
Tolcapone—Haemorrhage—Capecitabine—esophageal cancer	0.00117	0.00242	CcSEcCtD
Tolcapone—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.00116	0.00241	CcSEcCtD
Tolcapone—Hypoaesthesia—Capecitabine—esophageal cancer	0.00116	0.0024	CcSEcCtD
Tolcapone—CYP2C9—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00116	0.00991	CbGpPWpGaD
Tolcapone—Discomfort—Cisplatin—esophageal cancer	0.00116	0.0024	CcSEcCtD
Tolcapone—Pharyngitis—Capecitabine—esophageal cancer	0.00116	0.0024	CcSEcCtD
Tolcapone—Urinary tract disorder—Capecitabine—esophageal cancer	0.00115	0.00239	CcSEcCtD
Tolcapone—Oedema peripheral—Capecitabine—esophageal cancer	0.00115	0.00238	CcSEcCtD
Tolcapone—Urethral disorder—Capecitabine—esophageal cancer	0.00114	0.00237	CcSEcCtD
Tolcapone—COMT—Biological oxidations—CYP1B1—esophageal cancer	0.00113	0.00967	CbGpPWpGaD
Tolcapone—Oedema—Cisplatin—esophageal cancer	0.00112	0.00233	CcSEcCtD
Tolcapone—Infection—Cisplatin—esophageal cancer	0.00112	0.00231	CcSEcCtD
Tolcapone—COMT—Metapathway biotransformation—CYP1B1—esophageal cancer	0.00112	0.00954	CbGpPWpGaD
Tolcapone—Erythema multiforme—Capecitabine—esophageal cancer	0.0011	0.00229	CcSEcCtD
Tolcapone—Nervous system disorder—Cisplatin—esophageal cancer	0.0011	0.00228	CcSEcCtD
Tolcapone—Thrombocytopenia—Cisplatin—esophageal cancer	0.0011	0.00228	CcSEcCtD
Tolcapone—Tachycardia—Cisplatin—esophageal cancer	0.0011	0.00227	CcSEcCtD
Tolcapone—Skin disorder—Cisplatin—esophageal cancer	0.00109	0.00226	CcSEcCtD
Tolcapone—Tinnitus—Capecitabine—esophageal cancer	0.00109	0.00225	CcSEcCtD
Tolcapone—Hyperhidrosis—Cisplatin—esophageal cancer	0.00109	0.00225	CcSEcCtD
Tolcapone—Asthma—Methotrexate—esophageal cancer	0.00108	0.00225	CcSEcCtD
Tolcapone—COMT—Neuronal System—GNG7—esophageal cancer	0.00108	0.00925	CbGpPWpGaD
Tolcapone—Anorexia—Cisplatin—esophageal cancer	0.00107	0.00222	CcSEcCtD
Tolcapone—COMT—Biological oxidations—CYP19A1—esophageal cancer	0.00106	0.0091	CbGpPWpGaD
Tolcapone—Angiopathy—Capecitabine—esophageal cancer	0.00106	0.00219	CcSEcCtD
Tolcapone—Mediastinal disorder—Capecitabine—esophageal cancer	0.00105	0.00218	CcSEcCtD
Tolcapone—Hypotension—Cisplatin—esophageal cancer	0.00105	0.00218	CcSEcCtD
Tolcapone—COMT—Metapathway biotransformation—CYP19A1—esophageal cancer	0.00105	0.00897	CbGpPWpGaD
Tolcapone—Chills—Capecitabine—esophageal cancer	0.00105	0.00217	CcSEcCtD
Tolcapone—Arrhythmia—Capecitabine—esophageal cancer	0.00104	0.00216	CcSEcCtD
Tolcapone—Alopecia—Capecitabine—esophageal cancer	0.00103	0.00214	CcSEcCtD
Tolcapone—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.00102	0.00212	CcSEcCtD
Tolcapone—CYP2C9—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00102	0.00876	CbGpPWpGaD
Tolcapone—Mental disorder—Capecitabine—esophageal cancer	0.00102	0.00212	CcSEcCtD
Tolcapone—Dysuria—Methotrexate—esophageal cancer	0.00101	0.0021	CcSEcCtD
Tolcapone—COMT—Neuronal System—ALDH2—esophageal cancer	0.00101	0.00867	CbGpPWpGaD
Tolcapone—Paraesthesia—Cisplatin—esophageal cancer	0.00101	0.00209	CcSEcCtD
Tolcapone—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.00101	0.00209	CcSEcCtD
Tolcapone—Dyspnoea—Cisplatin—esophageal cancer	0.001	0.00208	CcSEcCtD
Tolcapone—Flatulence—Capecitabine—esophageal cancer	0.001	0.00207	CcSEcCtD
Tolcapone—Erectile dysfunction—Methotrexate—esophageal cancer	0.000999	0.00207	CcSEcCtD
Tolcapone—Dysgeusia—Capecitabine—esophageal cancer	0.000994	0.00206	CcSEcCtD
Tolcapone—Decreased appetite—Cisplatin—esophageal cancer	0.000977	0.00202	CcSEcCtD
Tolcapone—Muscle spasms—Capecitabine—esophageal cancer	0.000976	0.00202	CcSEcCtD
Tolcapone—Pneumonia—Methotrexate—esophageal cancer	0.000973	0.00202	CcSEcCtD
Tolcapone—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000971	0.00201	CcSEcCtD
Tolcapone—Infestation—Methotrexate—esophageal cancer	0.000967	0.002	CcSEcCtD
Tolcapone—Infestation NOS—Methotrexate—esophageal cancer	0.000967	0.002	CcSEcCtD
Tolcapone—Pain—Cisplatin—esophageal cancer	0.000961	0.00199	CcSEcCtD
Tolcapone—Vision blurred—Capecitabine—esophageal cancer	0.000957	0.00198	CcSEcCtD
Tolcapone—CYP2C9—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.000952	0.00814	CbGpPWpGaD
Tolcapone—Tremor—Capecitabine—esophageal cancer	0.000951	0.00197	CcSEcCtD
Tolcapone—Stomatitis—Methotrexate—esophageal cancer	0.000943	0.00195	CcSEcCtD
Tolcapone—Ill-defined disorder—Capecitabine—esophageal cancer	0.000942	0.00195	CcSEcCtD
Tolcapone—Anaemia—Capecitabine—esophageal cancer	0.000938	0.00194	CcSEcCtD
Tolcapone—Sweating—Methotrexate—esophageal cancer	0.000927	0.00192	CcSEcCtD
Tolcapone—Feeling abnormal—Cisplatin—esophageal cancer	0.000926	0.00192	CcSEcCtD
Tolcapone—Haematuria—Methotrexate—esophageal cancer	0.000922	0.00191	CcSEcCtD
Tolcapone—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000918	0.00785	CbGpPWpGaD
Tolcapone—CYP2C9—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.000918	0.00785	CbGpPWpGaD
Tolcapone—Malaise—Capecitabine—esophageal cancer	0.000916	0.0019	CcSEcCtD
Tolcapone—Epistaxis—Methotrexate—esophageal cancer	0.000912	0.00189	CcSEcCtD
Tolcapone—Vertigo—Capecitabine—esophageal cancer	0.000912	0.00189	CcSEcCtD
Tolcapone—Syncope—Capecitabine—esophageal cancer	0.000911	0.00189	CcSEcCtD
Tolcapone—Palpitations—Capecitabine—esophageal cancer	0.000897	0.00186	CcSEcCtD
Tolcapone—Loss of consciousness—Capecitabine—esophageal cancer	0.000892	0.00185	CcSEcCtD
Tolcapone—Body temperature increased—Cisplatin—esophageal cancer	0.000889	0.00184	CcSEcCtD
Tolcapone—Cough—Capecitabine—esophageal cancer	0.000886	0.00184	CcSEcCtD
Tolcapone—Hypertension—Capecitabine—esophageal cancer	0.000877	0.00182	CcSEcCtD
Tolcapone—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000875	0.00748	CbGpPWpGaD
Tolcapone—Haemoglobin—Methotrexate—esophageal cancer	0.000873	0.00181	CcSEcCtD
Tolcapone—Haemorrhage—Methotrexate—esophageal cancer	0.000868	0.0018	CcSEcCtD
Tolcapone—Arthralgia—Capecitabine—esophageal cancer	0.000864	0.00179	CcSEcCtD
Tolcapone—Myalgia—Capecitabine—esophageal cancer	0.000864	0.00179	CcSEcCtD
Tolcapone—Chest pain—Capecitabine—esophageal cancer	0.000864	0.00179	CcSEcCtD
Tolcapone—Pharyngitis—Methotrexate—esophageal cancer	0.000862	0.00179	CcSEcCtD
Tolcapone—Anxiety—Capecitabine—esophageal cancer	0.000861	0.00178	CcSEcCtD
Tolcapone—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000858	0.00178	CcSEcCtD
Tolcapone—Urinary tract disorder—Methotrexate—esophageal cancer	0.000857	0.00178	CcSEcCtD
Tolcapone—Discomfort—Capecitabine—esophageal cancer	0.000854	0.00177	CcSEcCtD
Tolcapone—Urethral disorder—Methotrexate—esophageal cancer	0.000851	0.00176	CcSEcCtD
Tolcapone—Dry mouth—Capecitabine—esophageal cancer	0.000845	0.00175	CcSEcCtD
Tolcapone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.000837	0.00716	CbGpPWpGaD
Tolcapone—Confusional state—Capecitabine—esophageal cancer	0.000836	0.00173	CcSEcCtD
Tolcapone—Oedema—Capecitabine—esophageal cancer	0.000829	0.00172	CcSEcCtD
Tolcapone—Hypersensitivity—Cisplatin—esophageal cancer	0.000828	0.00172	CcSEcCtD
Tolcapone—CYP2C9—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.000826	0.00706	CbGpPWpGaD
Tolcapone—Infection—Capecitabine—esophageal cancer	0.000823	0.00171	CcSEcCtD
Tolcapone—Erythema multiforme—Methotrexate—esophageal cancer	0.000821	0.0017	CcSEcCtD
Tolcapone—Shock—Capecitabine—esophageal cancer	0.000815	0.00169	CcSEcCtD
Tolcapone—Nervous system disorder—Capecitabine—esophageal cancer	0.000813	0.00168	CcSEcCtD
Tolcapone—Thrombocytopenia—Capecitabine—esophageal cancer	0.000811	0.00168	CcSEcCtD
Tolcapone—Tinnitus—Methotrexate—esophageal cancer	0.00081	0.00168	CcSEcCtD
Tolcapone—Tachycardia—Capecitabine—esophageal cancer	0.000809	0.00168	CcSEcCtD
Tolcapone—Asthenia—Cisplatin—esophageal cancer	0.000807	0.00167	CcSEcCtD
Tolcapone—Skin disorder—Capecitabine—esophageal cancer	0.000805	0.00167	CcSEcCtD
Tolcapone—Hyperhidrosis—Capecitabine—esophageal cancer	0.000801	0.00166	CcSEcCtD
Tolcapone—Anorexia—Capecitabine—esophageal cancer	0.00079	0.00164	CcSEcCtD
Tolcapone—Angiopathy—Methotrexate—esophageal cancer	0.000788	0.00163	CcSEcCtD
Tolcapone—Mediastinal disorder—Methotrexate—esophageal cancer	0.000783	0.00162	CcSEcCtD
Tolcapone—CYP2C9—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00078	0.00667	CbGpPWpGaD
Tolcapone—Chills—Methotrexate—esophageal cancer	0.000779	0.00161	CcSEcCtD
Tolcapone—Hypotension—Capecitabine—esophageal cancer	0.000774	0.0016	CcSEcCtD
Tolcapone—Diarrhoea—Cisplatin—esophageal cancer	0.000769	0.00159	CcSEcCtD
Tolcapone—Alopecia—Methotrexate—esophageal cancer	0.000767	0.00159	CcSEcCtD
Tolcapone—Mental disorder—Methotrexate—esophageal cancer	0.000761	0.00158	CcSEcCtD
Tolcapone—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000755	0.00156	CcSEcCtD
Tolcapone—Paraesthesia—Capecitabine—esophageal cancer	0.000744	0.00154	CcSEcCtD
Tolcapone—Dysgeusia—Methotrexate—esophageal cancer	0.00074	0.00153	CcSEcCtD
Tolcapone—Dyspnoea—Capecitabine—esophageal cancer	0.000739	0.00153	CcSEcCtD
Tolcapone—Dyspepsia—Capecitabine—esophageal cancer	0.000729	0.00151	CcSEcCtD
Tolcapone—CYP2C9—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.000721	0.00617	CbGpPWpGaD
Tolcapone—Decreased appetite—Capecitabine—esophageal cancer	0.00072	0.00149	CcSEcCtD
Tolcapone—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000715	0.00148	CcSEcCtD
Tolcapone—Vomiting—Cisplatin—esophageal cancer	0.000715	0.00148	CcSEcCtD
Tolcapone—Fatigue—Capecitabine—esophageal cancer	0.000714	0.00148	CcSEcCtD
Tolcapone—Vision blurred—Methotrexate—esophageal cancer	0.000712	0.00148	CcSEcCtD
Tolcapone—Rash—Cisplatin—esophageal cancer	0.000709	0.00147	CcSEcCtD
Tolcapone—Pain—Capecitabine—esophageal cancer	0.000709	0.00147	CcSEcCtD
Tolcapone—Constipation—Capecitabine—esophageal cancer	0.000709	0.00147	CcSEcCtD
Tolcapone—Dermatitis—Cisplatin—esophageal cancer	0.000708	0.00147	CcSEcCtD
Tolcapone—Ill-defined disorder—Methotrexate—esophageal cancer	0.000701	0.00145	CcSEcCtD
Tolcapone—Anaemia—Methotrexate—esophageal cancer	0.000699	0.00145	CcSEcCtD
Tolcapone—Feeling abnormal—Capecitabine—esophageal cancer	0.000683	0.00141	CcSEcCtD
Tolcapone—Malaise—Methotrexate—esophageal cancer	0.000682	0.00141	CcSEcCtD
Tolcapone—Vertigo—Methotrexate—esophageal cancer	0.000679	0.00141	CcSEcCtD
Tolcapone—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.000678	0.0058	CbGpPWpGaD
Tolcapone—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000678	0.0014	CcSEcCtD
Tolcapone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.000674	0.00577	CbGpPWpGaD
Tolcapone—Nausea—Cisplatin—esophageal cancer	0.000668	0.00138	CcSEcCtD
Tolcapone—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000665	0.00569	CbGpPWpGaD
Tolcapone—Cough—Methotrexate—esophageal cancer	0.00066	0.00137	CcSEcCtD
Tolcapone—Urticaria—Capecitabine—esophageal cancer	0.000658	0.00136	CcSEcCtD
Tolcapone—Body temperature increased—Capecitabine—esophageal cancer	0.000655	0.00136	CcSEcCtD
Tolcapone—Abdominal pain—Capecitabine—esophageal cancer	0.000655	0.00136	CcSEcCtD
Tolcapone—Chest pain—Methotrexate—esophageal cancer	0.000643	0.00133	CcSEcCtD
Tolcapone—Myalgia—Methotrexate—esophageal cancer	0.000643	0.00133	CcSEcCtD
Tolcapone—Arthralgia—Methotrexate—esophageal cancer	0.000643	0.00133	CcSEcCtD
Tolcapone—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000643	0.0055	CbGpPWpGaD
Tolcapone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000639	0.00132	CcSEcCtD
Tolcapone—Discomfort—Methotrexate—esophageal cancer	0.000636	0.00132	CcSEcCtD
Tolcapone—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000634	0.00542	CbGpPWpGaD
Tolcapone—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000626	0.00535	CbGpPWpGaD
Tolcapone—Confusional state—Methotrexate—esophageal cancer	0.000622	0.00129	CcSEcCtD
Tolcapone—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.00062	0.0053	CbGpPWpGaD
Tolcapone—Infection—Methotrexate—esophageal cancer	0.000613	0.00127	CcSEcCtD
Tolcapone—Hypersensitivity—Capecitabine—esophageal cancer	0.000611	0.00127	CcSEcCtD
Tolcapone—Nervous system disorder—Methotrexate—esophageal cancer	0.000605	0.00125	CcSEcCtD
Tolcapone—Thrombocytopenia—Methotrexate—esophageal cancer	0.000604	0.00125	CcSEcCtD
Tolcapone—Skin disorder—Methotrexate—esophageal cancer	0.000599	0.00124	CcSEcCtD
Tolcapone—Hyperhidrosis—Methotrexate—esophageal cancer	0.000596	0.00124	CcSEcCtD
Tolcapone—Asthenia—Capecitabine—esophageal cancer	0.000595	0.00123	CcSEcCtD
Tolcapone—Anorexia—Methotrexate—esophageal cancer	0.000588	0.00122	CcSEcCtD
Tolcapone—Pruritus—Capecitabine—esophageal cancer	0.000586	0.00121	CcSEcCtD
Tolcapone—Hypotension—Methotrexate—esophageal cancer	0.000576	0.00119	CcSEcCtD
Tolcapone—COMT—Metabolism—SLC52A3—esophageal cancer	0.000571	0.00489	CbGpPWpGaD
Tolcapone—COMT—Metabolism—BLVRB—esophageal cancer	0.000571	0.00489	CbGpPWpGaD
Tolcapone—Diarrhoea—Capecitabine—esophageal cancer	0.000567	0.00117	CcSEcCtD
Tolcapone—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000562	0.00116	CcSEcCtD
Tolcapone—Paraesthesia—Methotrexate—esophageal cancer	0.000554	0.00115	CcSEcCtD
Tolcapone—Dyspnoea—Methotrexate—esophageal cancer	0.00055	0.00114	CcSEcCtD
Tolcapone—Somnolence—Methotrexate—esophageal cancer	0.000548	0.00114	CcSEcCtD
Tolcapone—Dizziness—Capecitabine—esophageal cancer	0.000548	0.00114	CcSEcCtD
Tolcapone—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000547	0.00468	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.000544	0.00465	CbGpPWpGaD
Tolcapone—Dyspepsia—Methotrexate—esophageal cancer	0.000543	0.00113	CcSEcCtD
Tolcapone—Decreased appetite—Methotrexate—esophageal cancer	0.000536	0.00111	CcSEcCtD
Tolcapone—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000533	0.0011	CcSEcCtD
Tolcapone—Fatigue—Methotrexate—esophageal cancer	0.000532	0.0011	CcSEcCtD
Tolcapone—Pain—Methotrexate—esophageal cancer	0.000528	0.00109	CcSEcCtD
Tolcapone—Vomiting—Capecitabine—esophageal cancer	0.000527	0.00109	CcSEcCtD
Tolcapone—Rash—Capecitabine—esophageal cancer	0.000522	0.00108	CcSEcCtD
Tolcapone—Dermatitis—Capecitabine—esophageal cancer	0.000522	0.00108	CcSEcCtD
Tolcapone—Headache—Capecitabine—esophageal cancer	0.000519	0.00108	CcSEcCtD
Tolcapone—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000514	0.0044	CbGpPWpGaD
Tolcapone—Feeling abnormal—Methotrexate—esophageal cancer	0.000508	0.00105	CcSEcCtD
Tolcapone—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.000506	0.00432	CbGpPWpGaD
Tolcapone—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000504	0.00105	CcSEcCtD
Tolcapone—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000499	0.00426	CbGpPWpGaD
Tolcapone—Nausea—Capecitabine—esophageal cancer	0.000492	0.00102	CcSEcCtD
Tolcapone—Urticaria—Methotrexate—esophageal cancer	0.00049	0.00102	CcSEcCtD
Tolcapone—Body temperature increased—Methotrexate—esophageal cancer	0.000488	0.00101	CcSEcCtD
Tolcapone—Abdominal pain—Methotrexate—esophageal cancer	0.000488	0.00101	CcSEcCtD
Tolcapone—COMT—Metabolism—CA1—esophageal cancer	0.000486	0.00416	CbGpPWpGaD
Tolcapone—COMT—Metabolism—SLC10A2—esophageal cancer	0.000486	0.00416	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.00047	0.00402	CbGpPWpGaD
Tolcapone—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.000464	0.00396	CbGpPWpGaD
Tolcapone—Hypersensitivity—Methotrexate—esophageal cancer	0.000454	0.000942	CcSEcCtD
Tolcapone—COMT—Metabolism—CA2—esophageal cancer	0.000444	0.0038	CbGpPWpGaD
Tolcapone—Asthenia—Methotrexate—esophageal cancer	0.000443	0.000917	CcSEcCtD
Tolcapone—Pruritus—Methotrexate—esophageal cancer	0.000436	0.000904	CcSEcCtD
Tolcapone—Diarrhoea—Methotrexate—esophageal cancer	0.000422	0.000875	CcSEcCtD
Tolcapone—COMT—Metabolism—ADH7—esophageal cancer	0.000413	0.00353	CbGpPWpGaD
Tolcapone—COMT—Metabolism—PLCE1—esophageal cancer	0.000413	0.00353	CbGpPWpGaD
Tolcapone—Dizziness—Methotrexate—esophageal cancer	0.000408	0.000845	CcSEcCtD
Tolcapone—Vomiting—Methotrexate—esophageal cancer	0.000392	0.000813	CcSEcCtD
Tolcapone—Rash—Methotrexate—esophageal cancer	0.000389	0.000806	CcSEcCtD
Tolcapone—Dermatitis—Methotrexate—esophageal cancer	0.000389	0.000805	CcSEcCtD
Tolcapone—Headache—Methotrexate—esophageal cancer	0.000386	0.000801	CcSEcCtD
Tolcapone—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000383	0.00328	CbGpPWpGaD
Tolcapone—Nausea—Methotrexate—esophageal cancer	0.000366	0.000759	CcSEcCtD
Tolcapone—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000364	0.00312	CbGpPWpGaD
Tolcapone—COMT—Metabolism—ADH1B—esophageal cancer	0.000362	0.0031	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.00036	0.00308	CbGpPWpGaD
Tolcapone—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000352	0.00301	CbGpPWpGaD
Tolcapone—COMT—Metabolism—TYMP—esophageal cancer	0.000346	0.00296	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000342	0.00292	CbGpPWpGaD
Tolcapone—COMT—Metabolism—CYP26A1—esophageal cancer	0.000337	0.00288	CbGpPWpGaD
Tolcapone—COMT—Metabolism—ALOX15—esophageal cancer	0.000328	0.00281	CbGpPWpGaD
Tolcapone—COMT—Metabolism—TPI1—esophageal cancer	0.000313	0.00268	CbGpPWpGaD
Tolcapone—COMT—Metabolism—GSTO1—esophageal cancer	0.000313	0.00268	CbGpPWpGaD
Tolcapone—COMT—Metabolism—ALDOB—esophageal cancer	0.0003	0.00257	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.00029	0.00248	CbGpPWpGaD
Tolcapone—COMT—Metabolism—GAPDH—esophageal cancer	0.000289	0.00247	CbGpPWpGaD
Tolcapone—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000286	0.00245	CbGpPWpGaD
Tolcapone—COMT—Metabolism—CRABP1—esophageal cancer	0.000286	0.00245	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.00028	0.0024	CbGpPWpGaD
Tolcapone—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000273	0.00234	CbGpPWpGaD
Tolcapone—COMT—Metabolism—GNG7—esophageal cancer	0.000272	0.00233	CbGpPWpGaD
Tolcapone—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000269	0.0023	CbGpPWpGaD
Tolcapone—COMT—Metabolism—ALDH2—esophageal cancer	0.000255	0.00218	CbGpPWpGaD
Tolcapone—COMT—Metabolism—GSTT1—esophageal cancer	0.000243	0.00208	CbGpPWpGaD
Tolcapone—COMT—Metabolism—CYP2A6—esophageal cancer	0.00024	0.00205	CbGpPWpGaD
Tolcapone—COMT—Metabolism—PTGS1—esophageal cancer	0.000227	0.00195	CbGpPWpGaD
Tolcapone—COMT—Metabolism—ENO1—esophageal cancer	0.000227	0.00195	CbGpPWpGaD
Tolcapone—COMT—Metabolism—PSME1—esophageal cancer	0.000224	0.00192	CbGpPWpGaD
Tolcapone—COMT—Metabolism—PSME2—esophageal cancer	0.000224	0.00192	CbGpPWpGaD
Tolcapone—COMT—Metabolism—CYP1B1—esophageal cancer	0.000193	0.00165	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000189	0.00162	CbGpPWpGaD
Tolcapone—COMT—Metabolism—CYP19A1—esophageal cancer	0.000182	0.00156	CbGpPWpGaD
Tolcapone—COMT—Metabolism—HMOX1—esophageal cancer	0.000166	0.00142	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000165	0.00141	CbGpPWpGaD
Tolcapone—COMT—Metabolism—ABCB1—esophageal cancer	0.000159	0.00136	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000147	0.00125	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000147	0.00125	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000131	0.00112	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000125	0.00107	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—CA1—esophageal cancer	0.000125	0.00107	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—CA2—esophageal cancer	0.000114	0.000976	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000112	0.000954	CbGpPWpGaD
Tolcapone—COMT—Metabolism—CREBBP—esophageal cancer	0.000106	0.000911	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000106	0.000907	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000106	0.000907	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000105	0.000897	CbGpPWpGaD
Tolcapone—COMT—Metabolism—NOS3—esophageal cancer	9.53e-05	0.000815	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—ADH1B—esophageal cancer	9.3e-05	0.000795	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—TYMP—esophageal cancer	8.89e-05	0.00076	CbGpPWpGaD
Tolcapone—COMT—Metabolism—PTGS2—esophageal cancer	8.72e-05	0.000746	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—CYP26A1—esophageal cancer	8.65e-05	0.00074	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—ALOX15—esophageal cancer	8.43e-05	0.000721	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—GSTO1—esophageal cancer	8.04e-05	0.000688	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—TPI1—esophageal cancer	8.04e-05	0.000688	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—ALDOB—esophageal cancer	7.71e-05	0.000659	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—GAPDH—esophageal cancer	7.42e-05	0.000634	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—CRABP1—esophageal cancer	7.35e-05	0.000629	CbGpPWpGaD
Tolcapone—COMT—Metabolism—EP300—esophageal cancer	7.25e-05	0.00062	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—GNG7—esophageal cancer	6.99e-05	0.000598	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—ALDH2—esophageal cancer	6.55e-05	0.00056	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—GSTT1—esophageal cancer	6.23e-05	0.000533	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—CYP2A6—esophageal cancer	6.16e-05	0.000527	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	6.14e-05	0.000525	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—PTGS1—esophageal cancer	5.84e-05	0.0005	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—ENO1—esophageal cancer	5.84e-05	0.0005	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—PSME2—esophageal cancer	5.75e-05	0.000492	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—PSME1—esophageal cancer	5.75e-05	0.000492	CbGpPWpGaD
Tolcapone—COMT—Metabolism—PIK3CA—esophageal cancer	5.36e-05	0.000459	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	5.03e-05	0.00043	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—CYP1B1—esophageal cancer	4.97e-05	0.000425	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—CYP19A1—esophageal cancer	4.67e-05	0.000399	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—HMOX1—esophageal cancer	4.26e-05	0.000364	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	4.18e-05	0.000357	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—ABCB1—esophageal cancer	4.09e-05	0.00035	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	3.09e-05	0.000264	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—CREBBP—esophageal cancer	2.73e-05	0.000234	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—NOS3—esophageal cancer	2.45e-05	0.000209	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—PTGS2—esophageal cancer	2.24e-05	0.000191	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—EP300—esophageal cancer	1.86e-05	0.000159	CbGpPWpGaD
Tolcapone—CYP2C9—Metabolism—PIK3CA—esophageal cancer	1.38e-05	0.000118	CbGpPWpGaD
